Cellectar Biosciences, Inc. (NASDAQ: CLRB) Starts Presentation at 30th Annual ROTH Conference
Cellectar Biosciences (NASDAQ: CLRB) is developing phospholipid drug conjugates (“PDCs”) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar’s platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers, even sites of metastases. Cellectar’s lead therapeutic PDC, CLR 131, has been designated as an orphan drug by the US FDA and is being evaluated in a phase 1 clinical study in patients with refractory multiple myeloma and a phase 2 clinical study…







